Analysis on the efficacy and safety of sorophospbovir/vpativir with or without ribavirin in the treatment of patients with chronic hepatitis C
Objective To analyze the efficacy and safety of soophospbuvir/vpazivir with or without ribavirin in the treatment of chronic hepatitis C.Methods A total of 559 patients with chronic hepatitis C treated in Kunming Third People's Hospital from January 2019 to January 2023 were selected.RVR4 and SVR 12 of soophospbuvir/vpazivir alone or combined with ribavirin for four weeks and RVR of 12 weeks of drug discontinuance,biochemical indexes,degree of liver fibrosis and occurrence of adverse reactions were evaluated.Results The total SVR12 obtained at 12 weeks of drug discontinuance was 97.50％,of which the GT3 SVR12 was 97.63％;The SVR12 of CHC and CHC-CLC patients was 98.08％and 96.39％,respectively;There was no significant difference in SVR12 between the two groups(P＞0.05);After 12 weeks drug discontinuance,FIB-4 index and APRI score of all genomes decreased significantly compared with baseline,and the difference was statistically significant(P＜0.05).ALT,AST and GGT values decreased significantly from the baseline,and the difference was statistically significant(P＜0.05).The CKD stage of 39.29％(22/56)of patients was improved compared with that before treatment.There were 86 patients with adverse reactions(15.38％),including 47 patients with fatigue(8.41％),13 patients with headache,13(2.33％),9 patients with dizziness(1.61％),and 17 patients with mild hemolytic anemia(3.04％).All symptoms could be relieved after symptomatic treatment.Conclusions Soophospbovir/vpativir combined with or without ribavirin has good efficacy and safety in the treatment of patients with chronic hepatitis C.
万方数据
维普
